CoChat
Sign Up
Cited by 59

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Molecular Imaging and Nanotechnology—Emerging Tools in Diagnostics and Therapy

Woźniak, Marcin, Płoska, Agata, Siekierzycka, Anna, Dobrucki, Lawrence W., Kalinowski, Leszek, Dobrucki, Iwona T.·2022·International Journal of Molecular Sciences
DOI 10.3390/ijms23052658PMC PMC8910312
Open this paper in CoChat — free account

Abstract

Personalized medicine is emerging as a new goal in the diagnosis and treatment of diseases. This approach aims to establish differences between patients suffering from the same disease, which allows to choose the most effective treatment. Molecular imaging (MI) enables advanced insight into molecule interactions and disease pathology, improving the process of diagnosis and therapy and, for that reason, plays a crucial role in personalized medicine. Nanoparticles are widely used in MI techniques due to their size, high surface area to volume ratio, and multifunctional properties. After conjugation to specific ligands and drugs, nanoparticles can transport therapeutic compounds directly to their area of action and therefore may be used in theranostics—the simultaneous implementation of treatment and diagnostics. This review summarizes different MI techniques, including optical imaging, ultrasound imaging, magnetic resonance imaging, nuclear imaging, and computed tomography imaging with theranostics nanoparticles. Furthermore, it explores the potential use of constructs that enables multimodal imaging and track diseases in real time.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms23052658

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Multimodal multifunctional nanoparticles allow the in vivo imaging of anatomy, physiology, and molecular events at various spatiotemporal scales. Shown here are representative images of a mouse subjected to surgical ligation of the right femoral artery to induce hindlimb ischemia followed by the inflammatory response, which is assessed with a receptor for an advanced glycation end product (RAGE)-targeted nanoparticle-based multimodal agent labeled with both fluorophore (rhodamine) and radioisotope (64Cu). The anatomy was assessed with X-ray computed tomography (CT) imaging (A). In contrast, molecular proinflammatory events were quantitatively assessed in vivo with positron emission tomographic (PET) imaging (B), whole-body fluorescence (C), and Cherenkov luminescence (D).
Figure 1 Multimodal multifunctional nanoparticles allow the in vivo imaging of anatomy, physiology, and molecular events at various spatiotemporal scales. Shown here are representative images of a mouse subjected to surgical ligation of the right femoral artery to induce hindlimb ischemia followed by the inflammatory response, which is assessed with a receptor for an advanced glycation end product (RAGE)-targeted nanoparticle-based multimodal agent labeled with both fluorophore (rhodamine) and radioisotope (64Cu). The anatomy was assessed with X-ray computed tomography (CT) imaging (A). In contrast, molecular proinflammatory events were quantitatively assessed in vivo with positron emission tomographic (PET) imaging (B), whole-body fluorescence (C), and Cherenkov luminescence (D).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 79

  1. Massoud, 2003, Molecular imaging in living subjects: Seeing fundamental biological processes in a new light, Genes Dev., 17, 545, 10.1101/gad.1047403 · DOI
  2. Osborn, 2008, Advances in molecular imaging of atherosclerotic vascular disease, Curr. Opin. Cardiol., 23, 620, 10.1097/HCO.0b013e328310fc7e · DOI
  3. Weissleder, 2006, Molecular imaging in cancer, Science, 312, 1168, 10.1126/science.1125949 · DOI
  4. Weissleder, 2008, Imaging in the era of molecular oncology, Nature, 452, 580, 10.1038/nature06917 · DOI
  5. Xia, 2008, Nanomaterials at work in biomedical research, Nat. Mater., 7, 758, 10.1038/nmat2277 · DOI
  6. Lotfipour, 2021, Safety and Toxicity Issues of Therapeutically Used Nanoparticles from the Oral Route, Biomed. Res. Int., 2021, 9322282, 10.1155/2021/9322282 · DOI
  7. Abad, I., Conesa, C., and Sánchez, L. (2021). Development of Encapsulation Strategies and Composite Edible Films to Maintain Lactoferrin Bioactivity: A Review. Materials, 14. · DOI
  8. Lamri, M., Bhattacharya, T., Boukid, F., Chentir, I., Dib, A.L., Das, D., Djenane, D., and Gagaoua, M. (2021). Nanotechnology as a Processing and Packaging Tool to Improve Meat Quality and Safety. Foods, 10. · DOI
  9. Salem, 2022, The control of poultry salmonellosis using organic agents: An updated overview, Poult Sci., 101, 101716, 10.1016/j.psj.2022.101716 · DOI
  10. Talarska, P., Boruczkowski, M., and Żurawski, J. (2021). Current Knowledge of Silver and Gold Nanoparticles in Laboratory Research-Application, Toxicity, Cellular Uptake. Nanomaterials, 11. · DOI
  11. Ventola, 2017, Progress in Nanomedicine: Approved and Investigational Nanodrugs, Pharm. Ther., 42, 742
  12. Mitchell, 2021, Engineering precision nanoparticles for drug delivery, Nat. Rev. Drug Discov., 20, 101, 10.1038/s41573-020-0090-8 · DOI · Paper page
  13. Anselmo, 2019, Nanoparticles in the clinic: An update, Bioeng. Transl. Med., 4, e10143, 10.1002/btm2.10143 · DOI · Paper page
  14. Albalawi, 2021, Engineered Nanomaterials: The Challenges and Opportunities for Nanomedicines, Int. J. Nanomed., 16, 161, 10.2147/IJN.S288236 · DOI
  15. Abdellatif, 2021, Approved and marketed nanoparticles for disease targeting and applications in COVID-19, Nanotechnol. Rev., 10, 1941, 10.1515/ntrev-2021-0115 · DOI
  16. Foulkes, 2020, The regulation of nanomaterials and nanomedicines for clinical application: Current and future perspectives, Biomater. Sci., 8, 4653, 10.1039/D0BM00558D · DOI
  17. Kus-Liśkiewicz, M., Fickers, P., and Ben Tahar, I. (2021). Biocompatibility and Cytotoxicity of Gold Nanoparticles: Recent Advances in Methodologies and Regulations. Int. J. Mol. Sci., 22. · DOI
  18. EFSA Scientific Committee, More, S., Bampidis, V., Benford, D., Bragard, C., Halldorsson, T., Hernández-Jerez, A., Hougaard Bennekou, S., Koutsoumanis, K., and Lambré, C. (2021). Guidance on risk assessment of nanomaterials to be applied in the food and feed chain: Human and animal health. EFSA J., 19, e06768. · DOI
  19. Ji, Z., Guo, W., Sakkiah, S., Liu, J., Patterson, T.A., and Hong, H. (2021). Nanomaterial Databases: Data Sources for Promoting Design and Risk Assessment of Nanomaterials. Nanomaterials, 11. · DOI
  20. Laurent, 2010, Magnetic Iron Oxide Nanoparticles: Synthesis, Stabilization, Vectorization, Physicochemical Characterizations, and Biological Applications, Chem. Rev., 110, 2574, 10.1021/cr900197g · DOI
  21. Jokerst, 2011, Nanoparticle PEGylation for imaging and therapy, Nanomedicine, 6, 715, 10.2217/nnm.11.19 · DOI
  22. Brunner, 1972, Essential hypertension: Renin and aldosterone, heart attack and stroke, N. Engl. J. Med., 286, 441, 10.1056/NEJM197203022860901 · DOI
  23. Hapuarachchige, 2014, Bioorthogonal, two-component delivery systems based on antibody and drug-loaded nanocarriers for enhanced internalization of nanotherapeutics, Biomaterials, 35, 2346, 10.1016/j.biomaterials.2013.11.075 · DOI
  24. Hapuarachchige, 2016, Bioorthogonal two-component drug delivery in HER2(+) breast cancer mouse models, Sci. Rep., 6, 24298, 10.1038/srep24298 · DOI
  25. Luo, 2017, A Programmed Nanoparticle with Self-Adapting for Accurate Cancer Cell Eradication and Therapeutic Self-Reporting, Theranostics, 7, 1245, 10.7150/thno.18187 · DOI
  26. Paul, 2016, Photoresponsive real time monitoring silicon quantum dots for regulated delivery of anticancer drugs, J. Mater. Chem. B, 4, 521, 10.1039/C5TB02045J · DOI
  27. Wu, 2014, In Vivo and in Situ Tracking Cancer Chemotherapy by Highly Photostable NIR Fluorescent Theranostic Prodrug, J. Am. Chem. Soc., 136, 3579, 10.1021/ja412380j · DOI
  28. Guo, 2020, Intelligent nanoenzyme for T1-weighted MRI guided theranostic applications, Chem. Eng. J., 391, 123609, 10.1016/j.cej.2019.123609 · DOI
  29. Konopka, 2021, Molecularly targeted nanoparticles: An emerging tool for evaluation of expression of the receptor for advanced glycation end products in a murine model of peripheral artery disease, Cell. Mol. Biol. Lett., 26, 10, 10.1186/s11658-021-00253-0 · DOI
  30. Konopka, 2018, Multimodal Imaging of the Receptor for Advanced Glycation End-products with Molecularly Targeted Nanoparticles, Theranostics, 8, 5012, 10.7150/thno.24791 · DOI
  31. Kempen, 2015, Theranostic mesoporous silica nanoparticles biodegrade after pro-survival drug delivery and ultrasound/magnetic resonance imaging of stem cells, Theranostics, 5, 631, 10.7150/thno.11389 · DOI
  32. Gao, 2017, Oxygen-generating hybrid nanoparticles to enhance fluorescent/photoacoustic/ultrasound imaging guided tumor photodynamic therapy, Biomaterials, 112, 324, 10.1016/j.biomaterials.2016.10.030 · DOI
  33. Lee, 2017, Ultrasound-Enhanced siRNA Delivery Using Magnetic Nanoparticle-Loaded Chitosan-Deoxycholic Acid Nanodroplets, Adv. Healthc. Mater., 6, 1246, 10.1002/adhm.201601246 · DOI
  34. Yang, 2018, Multifunctional Bismuth Nanoparticles as Theranostic Agent for PA/CT Imaging and NIR Laser-Driven Photothermal Therapy, ACS Appl. Nano Mater., 1, 820, 10.1021/acsanm.7b00255 · DOI
  35. Ren, 2015, MRI-visible liposome nanovehicles for potential tumor-targeted delivery of multimodal therapies, Nanoscale, 7, 12843, 10.1039/C5NR02144H · DOI
  36. Ding, 2019, All-in-one theranostic nanoplatform with controlled drug release and activated MRI tracking functions for synergistic NIR-II hyperthermia-chemotherapy of tumors, Nano Res., 12, 2971, 10.1007/s12274-019-2540-3 · DOI
  37. Kim, 2010, A Drug-Loaded Aptamer−Gold Nanoparticle Bioconjugate for Combined CT Imaging and Therapy of Prostate Cancer, ACS Nano, 4, 3689, 10.1021/nn901877h · DOI
  38. Hedhli, 2017, Synthesis, Chemical Characterization and Multiscale Biological Evaluation of a Dimeric-cRGD Peptide for Targeted Imaging of αVβ3 Integrin Activity, Sci. Rep., 7, 3185, 10.1038/s41598-017-03224-8 · DOI
  39. Hedhli, 2018, Evaluation of a dimeric-cRGD peptide for targeted imaging of peripheral angiogenesis in diabetic mice, Sci. Rep., 8, 5401, 10.1038/s41598-018-23372-9 · DOI
  40. Konopka, 2020, Quantitative imaging of the receptor for advanced glycation end-products in prostate cancer, Eur. J. Nucl. Med. Mol. Imaging, 47, 2562, 10.1007/s00259-020-04721-1 · DOI
  41. Chen, 2013, In vivo tumor targeting and image-guided drug delivery with antibody-conjugated, radiolabeled mesoporous silica nanoparticles, ACS Nano, 7, 9027, 10.1021/nn403617j · DOI
  42. Liu, 2015, A Plasmonic Gold Nanostar Theranostic Probe for In Vivo Tumor Imaging and Photothermal Therapy, Theranostics, 5, 946, 10.7150/thno.11974 · DOI
  43. Zhao, 2015, Chlorotoxin-Conjugated Multifunctional Dendrimers Labeled with Radionuclide 131I for Single Photon Emission Computed Tomography Imaging and Radiotherapy of Gliomas, ACS Appl. Mater. Interfaces, 7, 19798, 10.1021/acsami.5b05836 · DOI
  44. Goins, 2017, Techniques for Loading Technetium-99m and Rhenium-186/188 Radionuclides into Preformed Liposomes for Diagnostic Imaging and Radionuclide Therapy, Methods Mol. Biol, 1522, 155, 10.1007/978-1-4939-6591-5_13 · DOI
  45. Debbage, 2008, Molecular imaging with nanoparticles: Giant roles for dwarf actors, Histochem. Cell Biol., 130, 845, 10.1007/s00418-008-0511-y · DOI
  46. Cai, 2019, Optical nano-agents in the second near-infrared window for biomedical applications, Chem. Soc. Rev., 48, 22, 10.1039/C8CS00494C · DOI · Paper page
  47. Chernov, 2017, Near-Infrared Fluorescent Proteins, Biosensors, and Optogenetic Tools Engineered from Phytochromes, Chem. Rev., 117, 6423, 10.1021/acs.chemrev.6b00700 · DOI
  48. Ding, 2017, Development of Ion Chemosensors Based on Porphyrin Analogues, Chem. Rev., 117, 2203, 10.1021/acs.chemrev.6b00021 · DOI
  49. Bremer, 2001, In vivo molecular target assessment of matrix metalloproteinase inhibition, Nat. Med., 7, 743, 10.1038/89126 · DOI · Paper page
  50. He, 2010, Near-infrared fluorescent nanoprobes for cancer molecular imaging: Status and challenges, Trends Mol. Med., 16, 574, 10.1016/j.molmed.2010.08.006 · DOI
  51. Yang, 2014, uPAR-targeted Optical Imaging Contrasts as Theranostic Agents for Tumor Margin Detection, Theranostics, 4, 106, 10.7150/thno.7409 · DOI
  52. Zhang, Q., Du, Y., Li, Y., Liang, X., Yang, X., and Tian, J. (2014, January 1–6). Gx1-conjugated endostar nanoparticle: A new drug delivery system for anti-colorectal cancer in vivo. Proceedings of the SPIE 8956, Reporters, Markers, Dyes, Nanoparticles, and Molecular Probes for Biomedical Applications VI, 895606, San Francisco, CA, USA. · DOI
  53. Jain, 2003, Nanodiagnostics: Application of nanotechnology in molecular diagnostics, Expert Rev. Mol. Diagn., 3, 153, 10.1586/14737159.3.2.153 · DOI
  54. Dahan, 2001, Time-gated biological imaging by use of colloidal quantum dots, Opt. Lett., 26, 825, 10.1364/OL.26.000825 · DOI
  55. Smith, 2006, Multicolor quantum dots for molecular diagnostics of cancer, Expert Rev. Mol. Diagn., 6, 231, 10.1586/14737159.6.2.231 · DOI
  56. Michalet, 2005, Quantum dots for live cells, in vivo imaging, and diagnostics, Science, 307, 538, 10.1126/science.1104274 · DOI
  57. Wang, 2014, A pH-sensitive theranostics system based on doxorubicin conjugated with the comb-shaped polymer coating of quantum dots, J. Mater. Sci., 49, 7539, 10.1007/s10853-014-8461-3 · DOI
  58. Chung, 2015, Recent Advances in Targeted, Self-Assembling Nanoparticles to Address Vascular Damage Due to Atherosclerosis, Adv. Healthc. Mater., 4, 2408, 10.1002/adhm.201500126 · DOI
  59. Janib, 2010, Imaging and drug delivery using theranostic nanoparticles, Adv. Drug Deliv. Rev., 62, 1052, 10.1016/j.addr.2010.08.004 · DOI
  60. Shubayev, 2009, Magnetic nanoparticles for theragnostics, Adv. Drug Deliv. Rev., 61, 467, 10.1016/j.addr.2009.03.007 · DOI
  61. Sun, 2008, Magnetic nanoparticles in MR imaging and drug delivery, Adv. Drug Deliv. Rev., 60, 1252, 10.1016/j.addr.2008.03.018 · DOI
  62. Veiseh, 2010, Design and fabrication of magnetic nanoparticles for targeted drug delivery and imaging, Adv. Drug Deliv. Rev., 62, 284, 10.1016/j.addr.2009.11.002 · DOI
  63. Custers, 2010, Block-copolymer-stabilized iodinated emulsions for use as CT contrast agents, Biomaterials, 31, 6537, 10.1016/j.biomaterials.2010.04.056 · DOI
  64. Elrod, 2009, An iodinated liposomal computed tomographic contrast agent prepared from a diiodophosphatidylcholine lipid, Nanomed. Nanotechnol. Biol. Med., 5, 42, 10.1016/j.nano.2008.06.007 · DOI
  65. Kong, 2007, Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging, Biomaterials, 28, 5555, 10.1016/j.biomaterials.2007.08.044 · DOI
  66. Aviv, 2009, Radiopaque iodinated copolymeric nanoparticles for X-ray imaging applications, Biomaterials, 30, 5610, 10.1016/j.biomaterials.2009.06.038 · DOI
  67. Galperin, 2007, Radiopaque iodinated polymeric nanoparticles for X-ray imaging applications, Biomaterials, 28, 4461, 10.1016/j.biomaterials.2007.06.032 · DOI
  68. Skajaa, 2010, High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis, Arterioscler. Thromb. Vasc. Biol., 30, 169, 10.1161/ATVBAHA.108.179275 · DOI
  69. Bao, 2003, A novel liposome radiolabeling method using 99mTc-“SNS/S” complexes: In vitro and in vivo evaluation, J. Pharm. Sci., 92, 1893, 10.1002/jps.10441 · DOI
  70. Bao, 2006, Potential use of drug carried-liposomes for cancer therapy via direct intratumoral injection, Int. J. Pharm., 316, 162, 10.1016/j.ijpharm.2006.02.039 · DOI
  71. Goins, 1993, Biodistribution and imaging studies of technetium-99m-labeled liposomes in rats with focal infection, J. Nucl. Med. Off. Publ. Soc. Nucl. Med., 34, 2160
  72. Goins, 1994, Use of technetium-99m-liposomes in tumor imaging, J. Nucl. Med.Off. Publ. Soc. Nucl. Med., 35, 1491
  73. Phillips, 2002, Assessment of liposome delivery using scintigraphic imaging, J. Liposome Res., 12, 71, 10.1081/LPR-120004779 · DOI
  74. Phillips, 2001, Use of (99m) Tc-labeled liposomes encapsulating blue dye for identification of the sentinel lymph node, J. Nucl. Med.Off. Publ. Soc. Nucl. Med., 42, 446
  75. Kovacs, 2015, Development of (177) Lu-DOTA-Dendrimer and Determination of Its Effect on Metal and Ion Levels in Tumor Tissue, Cancer Biother. Radiopharm., 30, 405
  76. Reis, 2006, Nanoencapsulation I. Methods for preparation of drug-loaded polymeric nanoparticles, Nanomed. Nanotechnol. Biol. Med., 2, 8, 10.1016/j.nano.2005.12.003 · DOI
  77. Yang, 2017, New Potential In Situ Anticancer Agent Derived from [188Re] rhenium Nitro-Imidazole Ligand Loaded 5th Generation Poly-L-Lysine Dendrimer for Treatment of Transplanted Human Liver Carcinoma in Nude Mice, Drug Des. Open Access, 6, 1
  78. Chen, 2014, In vivo tumor vasculature targeted PET/NIRF imaging with TRC105(Fab)-conjugated, dual-labeled mesoporous silica nanoparticles, Mol. Pharm., 11, 4007, 10.1021/mp500306k · DOI
  79. Goel, 2014, VEGF₁₂₁-conjugated mesoporous silica nanoparticle: A tumor targeted drug delivery system, ACS Appl. Mater. Interfaces, 6, 21677, 10.1021/am506849p · DOI

Cited by

Sorted by citations

Metadata

Authors
Woźniak, M., Płoska, A., Siekierzycka, A., Dobrucki, L. W., Kalinowski, L., & Dobrucki, I. T.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-02-28
Volume
23
Issue
5
Pages
2658
ISSN
1422-0067
DOI
10.3390/ijms23052658
PMC
PMC8910312
Cited by
59
References
3
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)
Funders
  • National Science Center (2019/33/B/NZ7/02699)
  • Ministry of Science and Higher Education (DIR/WK/2017/01, 10/E-389/SPUB/SP/2020)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review